Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...295296297298299300301302303304305...10661067»
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease. (Pubmed Central) -  Jul 12, 2022   
    These data suggest that time-sensitive mucolytic agents, specific pathway inhibitors, or corticosteroid administration may be therapeutic for COVID-19 lung disease. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Early and aggressive treatment may modify anti Hu associated encephalitis prognosis. (Pubmed Central) -  Jul 12, 2022   
    Aggressive immunotherapy including dexamethasone, rituximab and IV immunoglobulins were used and a marked neurological improvement soon after 9 months of onset was observed with a child who was able to go back to school. The short delay between diagnosis and start of aggressive immunotherapy demonstrate the paramount importance of early diagnosis and early specific therapy after onset of symptoms.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Trial completion date, Trial primary completion date:  Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma (clinicaltrials.gov) -  Jul 12, 2022   
    P2,  N=28, Recruiting, 
    Trial completion date: Oct 2028 --> Oct 2029 | Initiation date: Apr 2022 --> Oct 2022 | Trial primary completion date: Oct 2028 --> Oct 2029 Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2022 --> Jul 2023
  • ||||||||||  dexamethasone / Generic mfg., ropivacaine / Generic mfg.
    Enrollment change, Trial completion date, Trial primary completion date:  PAIN-RELIEF: Scalp Infiltration With Dexamethasone Plus Ropivacaine for Post-craniotomy Pain (clinicaltrials.gov) -  Jul 12, 2022   
    P4,  N=90, Not yet recruiting, 
    Trial completion date: Jan 2034 --> Nov 2031 N=216 --> 90 | Trial completion date: Nov 2022 --> Sep 2023 | Trial primary completion date: May 2022 --> May 2023
  • ||||||||||  dexamethasone / Generic mfg., fludrocortisone / Generic mfg.
    New P3 trial:  Mineralocorticoid Use in COVID-19 Patients (clinicaltrials.gov) -  Jul 12, 2022   
    P3,  N=10, Completed, 
  • ||||||||||  budesonide/formoterol / Generic mfg., beclometasone/formoterol / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  FORSYYN: Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (clinicaltrials.gov) -  Jul 11, 2022   
    P3,  N=750, Completed, 
    N=216 --> 90 | Trial completion date: Nov 2022 --> Sep 2023 | Trial primary completion date: May 2022 --> May 2023 Recruiting --> Completed | Trial completion date: Dec 2022 --> May 2022 | Trial primary completion date: Nov 2022 --> May 2022
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  A Poly (Caprolactone)-Cellulose Nanocomposite Hydrogel for Transdermal Delivery of Hydrocortisone in Treating Psoriasis Vulgaris. (Pubmed Central) -  Jul 10, 2022   
    Keratinocyte skin cells were treated with HCT-loaded SMS-PCL nanoparticles encapsulated with CMC; the results indicated that the synthesized drug-delivery system was less toxic to the keratinocyte cells compared to HCT. The combined trials and results from the formulation of HCT-loaded SMS-PCL nanoparticles encapsulated with CMC showed evidence that this hydrogel can be utilized as a potentially invaluable formulation for transdermal drug delivery of HCT, with improved efficacy and patient conformity.
  • ||||||||||  budesonide / Generic mfg., fluticasone / Generic mfg.
    High dose inhaled steroids: is there a risk of adrenal insufficiency? (Exchange 8-10, upper level) -  Jul 10, 2022 - Abstract #BTSSummer2022BTS_Summer_40;    
    Patients on high dose steroid inhalers at risk of adrenal suppression should carry a steroid emergency card and advice on how to detect and prevent an adrenal crisis is crucial. Challenges still exist on how to manage these patients.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Journal:  Multiple Myeloma: 2022 update on Diagnosis, Risk-stratification and Management. (Pubmed Central) -  Jul 10, 2022   
    Standard risk patients need lenalidomide maintenance, while bortezomib plus lenalidomide maintenance is needed for high-risk myeloma. A triplet regimen is usually needed at relapse, with the choice of regimen varying with each successive relapse.
  • ||||||||||  prednisolone / Generic mfg.
    Journal:  Closantel retinal toxicity: Recovery from severe vision loss after corticosteroid therapy. (Pubmed Central) -  Jul 10, 2022   
    Closantel is a potentially toxic drug causing destruction of the neurosensory retina and visual disturbances. We suggest eye-care personnel awareness regarding the risk of Closantel-induced retinal toxicity and prompt treatment with systemic steroids should be considered.
  • ||||||||||  clodronate disodium / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    Journal:  Glucocorticoid-induced expansion of classical monocytes contributes to bone loss. (Pubmed Central) -  Jul 10, 2022   
    In this study, GIOP was established in rats and mice by daily methylprednisolone injection, and monocyte subsets were analyzed by flow cytometry...Deletion of classical monocytes by clodronate liposome treatment prevented GIOP via inhibition of osteoclastogenesis and restoration of CD31endomucin vessels...In vitro treatment with GCs increased both the percentage and absolute number of monocytes and promoted their proliferation. In summary, classical monocytes mediated GC-induced bone loss and are a potential target for therapeutic intervention in GIOP treatment.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  The Development of a Protocol for Critical Illness-Related Corticosteroid Insufficiency (CIRCI) at a Tertiary Hospital. (Pubmed Central) -  Jul 10, 2022   
    The definitive diagnosis of CIRCI is established through a random serum cortisol <10 mcg/dL or increase in cortisol of <9 mcg/dL at 60 minutes after a 250 mcg ACTH stimulation test in patients with indeterminate random cortisol levels. The presence of refractory shock unresponsive to fluid resuscitation and vasopressors should warrant the clinical suspicion for the existence of CIRCI and should trigger a cascade of management strategies.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Risk Factors Associated With Inadequate Brain Relaxation in Craniotomy for Surgery of Supratentorial Tumors. (Pubmed Central) -  Jul 9, 2022   
    The presence of refractory shock unresponsive to fluid resuscitation and vasopressors should warrant the clinical suspicion for the existence of CIRCI and should trigger a cascade of management strategies. The use of preoperative dexamethasone was associated with improved brain relaxation, whereas the presence of a preoperative midline shift and a higher level of hemoglobin were associated with poor brain relaxation.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Curcumin-Encapsulated Chitosan-Coated Nanoformulation as an Improved Otoprotective Strategy for Ototoxic Hearing Loss. (Pubmed Central) -  Jul 9, 2022   
    The obtained results revealed that both CUR-NPs provided otoprotection in vitro and in vivo, and their effective doses in guinea pigs were much less than that of dexamethasone, which was clinically used to treat HL...Lastly, the protective effect of CUR nanoformulations was further validated via inhibition of Caspase-3 and Bax activation, thereby reducing the concentration of reactive oxygen species and protecting mitochondrial integrity in hair cells. Collectively, CUR-CS/PLGA NPs demonstrated potent and lasting effects against ototoxic HL, making our novel formulation a promising candidate for the alleviation of sensorineural HL.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Analysis of the effects of turmeric and symbiotic consumption on bones of rats submitted to the use of dexamethasone. (Pubmed Central) -  Jul 9, 2022   
    Collectively, CUR-CS/PLGA NPs demonstrated potent and lasting effects against ototoxic HL, making our novel formulation a promising candidate for the alleviation of sensorineural HL. It was possible to verify that curcumin showed promising effects related to the increase in bone strength and mineralization, mitigating the deleterious effects caused by dexamethasone, when used simultaneously with this drug.